Equillium Announces Poster Presentations at the 7th International AHR Conference
Key Highlights
- ➤Equillium (EQ) will present new preclinical EQ504 data in two posters at the 7th International AHR Conference
- ➤EQ504 protected intestinal barrier integrity and regulated inflammatory chemokines across ulcerative-colitis models
- ➤EQ504 suppressed pathogenic Th17/M1 responses while enhancing regulatory immune pathways
- ➤EQ504 may support targeted local delivery for ulcerative colitis and inflammatory lung diseases
Expert Statements
Stephen Connelly, Chief Scientific Officer of Equillium
“These studies further characterize the multi-modal activity of EQ504, including its effects on epithelial barrier repair and key immune pathways involved in inflammation.”
Stephen Connelly, Chief Scientific Officer of Equillium
“Together, the findings add to the growing body of preclinical data supporting the potential of selective AhR modulation as an approach to treating ulcerative colitis.”
LA JOLLA, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new preclinical data from its EQ504 program will be presented in two posters at the 7th International AHR Conference, taking place September 29 to October 2, 2026, in Porto, Portugal.
“These studies further characterize the multi-modal activity of EQ504, including its effects on epithelial barrier repair and key immune pathways involved in inflammation,” said Dr. Stephen Connelly, Chief Scientific Officer of Equillium. “Together, the findings add to the growing body of preclinical data supporting the potential of selective AhR modulation as an approach to treating ulcerative colitis.”
Get started
Create a free account to read the full story.